|
市場調査レポート
商品コード
1384987
ペンニードルの世界市場規模、シェア、産業動向分析レポート:タイプ別、設定別、用途別、長さ別、購入形態別、地域別展望と予測、2023年~2030年Global Pen Needles Market Size, Share & Industry Trends Analysis Report By Type, By Setting, By Application, By Length (8mm, 6mm, 5mm, 10mm, 12mm, and 4mm), By Mode of Purchase, By Regional Outlook and Forecast, 2023 - 2030 |
||||||
|
ペンニードルの世界市場規模、シェア、産業動向分析レポート:タイプ別、設定別、用途別、長さ別、購入形態別、地域別展望と予測、2023年~2030年 |
出版日: 2023年10月31日
発行: KBV Research
ページ情報: 英文 529 Pages
納期: 即納可能
![]() |
ペンニードルの市場規模は、予測期間中にCAGR 9.4%で成長し、2030年には31億米ドルに達すると予測されます。2022年の市場規模は8,693万900ユニットで、成長率は9.1%である(2019年~2022年)。
KBV Cardinalのマトリックスに示された分析によると、Novo Nordisk A/Sが同市場の先駆者です。2023年9月、Novo Nordisk A/Sは世界的製薬会社のAspen Pharmacare Holdings Limitedと提携しました。このパートナーシップは、アフリカ大陸内の患者に手頃な価格のヒトインスリンを提供することを目的としています。Terumo Corporation、B. Braun Melsungen AG、Embecta Corp.などの企業が、この市場における主要なイノベーターです。
COVID-19の影響分析
COVID-19パンデミックは市場に大きな影響を与えました。パンデミックによって対面でのヘルスケア受診が制限されたため、糖尿病やその他の慢性疾患を抱える多くの人々が遠隔診療を利用し、遠隔診察や処方更新を受けるようになっています。その結果、在宅医療を促進するため、ペン型注射針のような自己投与型医療機器の需要が増加しました。パンデミックは世界のサプライチェーンを混乱させ、ペン型注射針を含む医療機器の製造と流通に遅れをもたらしました。このため、これらの重要なヘルスケア製品の一時的な品不足と流通上の課題が生じた。このため、ペンニードルの採用が急増したと思われます。このような要因から、パンデミック後も市場は上昇すると思われます。
市場成長要因
技術進歩の拡大
ペン型注射針に施された特殊コーティングは、注射プロセスをよりスムーズにし、痛みを軽減することができます。これらのコーティングは、注射針が皮膚をより簡単に滑るのを助けることができます。技術の進歩により、メーカーは個々の患者のニーズを満たすために様々な仕様のペンニードルを提供できるようになっています。これらの針は、しばしば異なるペン型器具と互換性があり、汎用性を高めています。製造工程の改善により、ペンニードルの製造における精度と品質が向上し、一貫した信頼性の高い性能が確保されています。一部のペンデバイスとペンニードルはデジタルヘルス技術と統合されており、患者が注射を追跡し、より効果的に健康をモニターできるようになっています。技術の進歩に伴い、同市場はさらなる成長と革新を遂げると思われます。
糖尿病有病率の増加
座りがちな生活、不健康な食生活、ストレスの増加などを特徴とする現代のライフスタイルは、肥満の増加、ひいては2型糖尿病の増加に寄与しています。世界人口の高齢化に伴い、2型糖尿病を発症するリスクも高まっています。高齢者はこの疾患にかかりやすいです。肥満は2型糖尿病の実質的な危険因子です。世界の肥満が糖尿病患者の増加につながっています。都市化が進むにつれて、座りっぱなしの生活を送る人が増え、それがインスリン抵抗性と2型糖尿病の発症の一因となっています。糖尿病の有病率の増加は市場に大きな影響を及ぼし、高度なペン型注射針の開発と様々なヘルスケア環境での使用の拡大を促進しています。
市場抑制要因
代替ドラッグデリバリーへの嗜好
代替ドラッグデリバリー方法、特に特定の薬剤に対する嗜好は、ペン型注射針との市場競争という結果を招きかねないです。メーカーは競争力を維持するために、嗜好の変化に適応し、技術革新を行わなければならないです。特に代替送達方法が普及している、あるいは好まれている地域では、市場が飽和状態になる可能性があります。メーカーは提供する製品を多様化する必要があります。注射療法のアドヒアランスに悩む患者もいるため、ヘルスケアプロバイダーは患者のコンプライアンスを向上させる代替方法を模索する必要があります。そのためには患者の教育と支援が必要です。以上のような要因が、今後数年間の市場成長の課題となると思われます。
タイプ別展望
タイプ別では、市場は標準ペンニードルと安全ペンニードルに区分されます。2022年には、標準ペンニードル・セグメントが最大の収益シェアで市場を独占しました。標準ペンニードルは、日常的な注射のために設計されており、さまざまな患者のニーズを満たすために様々な仕様があります。標準的なペン型注射針は1回限りの使用を目的としています。針の長さとゲージの選択は、個人の好み、体型、ヘルスケアプロバイダーの推奨に基づいています。快適さのために短くて細い針を好む人もいれば、適切な皮下インスリン送達のために長い針を必要とする人もいます。
セッティングの展望
設定に基づき、市場は在宅ケア、病院・診療所、その他に分けられます。病院・診療所セグメントは2022年の市場で大きな収益シェアを獲得しました。病院・診療所では、糖尿病管理のためにペン型注射針が広く使用されています。このトレーニングにより、患者は安全かつ効果的に薬剤を自己投与できるようになります。病院や診療所でペンニードルを使用することは、様々な病状を持つ患者に効果的で便利な皮下投薬管理を提供するために極めて重要です。患者のニーズと投与される薬剤によって、ペンニードルのタイプ、長さ、ゲージの選択が決定されます。
用途別展望
用途別では、インスリン、グルカゴン様ペプチド-1(GLP-1)、成長ホルモン、骨粗鬆症、その他に分類されます。2022年には、インスリン・セグメントが市場で最も高い収益シェアを記録しました。インスリン療法では、インスリンを皮下投与します。これは、皮膚の下の脂肪組織にインスリンを注射することを意味します。インスリン療法にペンニードルを使用することで、個人のライフスタイル、インスリンレジメン、ヘルスケアプロバイダーの推奨に基づいて糖尿病管理を個別化することができます。ペンニードルによるインスリン治療は、糖尿病患者が適切な血糖コントロールを維持し、高血糖や低血糖に伴う合併症を予防するために極めて重要です。
長さの展望
長さによって、市場は4mm、5mm、6mm、8mm、10mm、12mmに細分化されます。12mmセグメントが2022年の市場で大きな収益シェアを占めると予測されます。1型と2型の糖尿病患者は、インスリンの自己投与に12mmのペン型注射針を使用することが多いです。これらの針の長さが長いため、皮膚が厚い人や皮下脂肪が多い人でも、確実に皮下組織にインスリンを投与することができます。長い注射針は、薬液の漏れや浅すぎる注射のリスクを減らし、薬液が目的の組織層に効果的に送達されるようにするのに役立ちます。
購入形態の展望
購入形態によって、市場は処方箋ベース、市販薬、オンライン購入、その他に分類されます。2022年には、市販薬が市場で最大の売上シェアを占めました。市販(OTC)ペンニードルは、ヘルスケアプロバイダーからの処方箋を必要とせずに購入できるペンニードルです。OTCペンニードルの利用可能性は、治療のためにこれらのデバイスを必要とする個人、特にインスリン投与を必要とする糖尿病患者にとって、適切で利用しやすい選択肢を提供します。
地域別展望
地域別に見ると、市場は北米、欧州、アジア太平洋、LAMEAで分析されます。2022年には、北米地域が最大の収益シェアで市場を独占しました。北米市場の成長は、主に糖尿病の高い有病率、インスリンペンの採用の増加、伝統的な注射器よりもペンニードルの利点に関する意識の上昇などの要因によって駆動されます。さらに、長さ、ゲージ、デザインの異なる様々なペン型注射針が入手可能であること、Becton, Dickinson and Company、Novo Nordisk A/S、Owen Mumfordといった定評ある市場プレイヤーの存在が北米市場の成長に寄与しています。
The Global Pen Needles Market size is expected to reach $3.1 billion by 2030, rising at a market growth of 9.4% CAGR during the forecast period. In the year 2022, the market attained a volume of 86,930.9 thousand Units experiencing a growth of 9.1% (2019-2022).
The trend toward self-administration empowers patients to manage their health and treatment independently. This is particularly evident in diabetes management, where self-administration of insulin has become the norm for many patients. Therefore, Insulin segment generated $1,122.2 million revenue in the market in 2022. As a result, self-administration can lead to cost savings for healthcare systems by reducing the need for frequent clinical visits and healthcare professional assistance. This is beneficial, especially in healthcare settings with limited resources.
The major strategies followed by the market participants are Partnerships as the key developmental strategy to keep pace with the changing demands of end users. For instance, In May, 2023, Embecta Corp. came into partnership with Tidepool, to develop an automated insulin delivery system for the treatment of type 2 diabetes. The two companies would combine their respective offerings to facilitate glucose management within the patients to achieve the aim of their partnership. Moreover, In November, 2021, Terumo Corporation signed a partnership with Diabeloop, to provide Automated Insulin Delivery solutions to European customers. The partnership expands the two company's geographical footprint.
Based on the Analysis presented in the KBV Cardinal matrix; Novo Nordisk A/S is the forerunner in the Market. In September, 2023, Novo Nordisk A/S came into partnership with Aspen Pharmacare Holdings Limited, a global pharmaceutical company. The partnership aimed at providing affordable human insulin to patients within the African continent. Companies such as Terumo Corporation, B. Braun Melsungen AG and Embecta Corp. are some of the key innovators in the Market.
COVID-19 Impact Analysis
The COVID-19 pandemic had a significant impact on the market. With the pandemic limiting in-person healthcare visits, many people with diabetes and other chronic conditions turned to telemedicine for remote consultations and prescription renewals. As a result, the demand for self-administered medical devices like pen needles increased to facilitate home-based care. The pandemic disrupted global supply chains, leading to delays in the manufacturing and distribution of medical devices, including pen needles. This caused temporary shortages and distribution challenges for these critical healthcare products. This likely led to a surge in the adoption of these needles. Due to such factors, the market will uplift after the pandemic.
Market Growth Factors
Expansion of technological advancements
Special coatings on pen needles can make the injection process smoother and less painful. These coatings can help the needle glide through the skin more easily. Technological advancements have enabled manufacturers to offer various pen needles with varying specifications to meet individual patient needs. These needles are often compatible with different pen devices, enhancing their versatility. Improved manufacturing processes have increasing precision and quality in pen needle production, ensuring consistent and reliable performance. Some pen devices and pen needles are integrated with digital health technologies, allowing patients to track their injections and monitor their health more effectively. As technology advances, the market will likely see further growth and innovation.
Growing prevalence of diabetes
Modern lifestyles characterized by sedentary behavior, unhealthy dietary habits, and increased stress levels have contributed to a rise in obesity and, consequently, type 2 diabetes. As the global population ages, the risk of developing type 2 diabetes increases. Elderly adults are more susceptible to this condition. Obesity is a substantial risk factor for type 2 diabetes. Global obesity has led to a higher incidence of diabetes cases. Increasing urbanization has led to more people leading sedentary lives, which can contribute to insulin resistance and the development of type 2 diabetes. The increasing prevalence of diabetes has a significant impact on the market, driving both the development of advanced pen needles and the expansion of their use in various healthcare settings.
Market Restraining Factors
Preference for alternative drug delivery method
The preference for alternative drug delivery methods, especially for specific medications, can result in competition for market share with pen needles. Manufacturers must adapt to changing preferences and innovate to remain competitive. The market may become saturated, especially in regions with prevalent or preferred alternative delivery methods. Manufacturers need to diversify their product offerings. Some patients struggle with adherence to injection regimens, leading healthcare providers to explore alternative methods that improve patient compliance. This requires patient education and support. The above factors will challenge market growth in the coming years.
Type Outlook
On the basis of type, the market is segmented into standard pen needles and safety pen needles. In 2022, the standard pen needles segment dominated the market with the maximum revenue share. Standard pen needles are designed for routine injections and come in various specifications to meet the needs of different patients. Standard pen needles are intended for one-time use. The needle length and gauge choice are based on individual preferences, body type, and healthcare provider recommendations. Some individuals prefer shorter and thinner needles for comfort, while others require longer needles for proper subcutaneous insulin delivery.
Setting Outlook
Based on setting, the market is divided into homecare, hospitals & clinics, and others. The hospitals & clinics segment garnered a significant revenue share in the market in 2022. Hospitals and clinics use pen needles extensively for diabetes management. This training ensures that patients can safely and effectively self-administer medications. Using pen needles in hospitals and clinics is crucial for providing effective and convenient subcutaneous medication administration to patients with various medical conditions. The patient's needs and the medication administered determine the pen needle type, length, and gauge choice.
Application Outlook
By application, the market is classified into insulin, glucagon-like-peptide-1 (GLP-1), growth hormone, osteoporosis, and others. In 2022, the insulin segment registered the highest revenue share in the market. Insulin therapy involves the subcutaneous administration of insulin, which means injecting insulin into the fatty tissue beneath the skin. Using pen needles in insulin therapy allows individuals to personalize their diabetes management based on their lifestyle, insulin regimen, and healthcare provider recommendations. Insulin therapy with pen needles is crucial for individuals with diabetes to maintain proper blood glucose control and prevent complications associated with high or low blood sugar levels.
Length Outlook
Based on length, the market is fragmented into 4mm, 5mm, 6mm, 8mm, 10mm, and 12mm. The 12mm segment projected a significant revenue share in the market in 2022. People with diabetes, both type 1 and type 2, often use 12mm pen needles to self-administer insulin. The longer length of these needles ensures that the insulin is delivered into the subcutaneous tissue, even in individuals with thicker skin or more subcutaneous fat. Longer needles can help reduce the risk of medication leakage or being injected too shallowly, ensuring that the medication is effectively delivered to the intended tissue layer.
Mode of Purchase Outlook
On the basis of mode of purchase, the market is categorised into prescription-based, over the counter, online purchase, and others. In 2022, the over the counter segment generated the largest revenue share in the market. Over-the-counter (OTC) pen needles are pen needles that can be purchased without the need for a prescription from a healthcare provider. The availability of OTC pen needles provides a suitable and accessible option for individuals who require these devices for their medical treatment, particularly those with diabetes who need insulin administration.
Regional Outlook
Region-wise, the market is analysed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the North America region dominated the market with the maximum revenue share. The growth of the North America market is primarily driven by factors such as the high prevalence of diabetes, the increase in the adoption of insulin pens, and the rise in awareness regarding the benefits of pen needles over traditional syringes. Moreover, the availability of a various range of pen needles with different lengths, gauges, and designs and the presence of established market players such as Becton, Dickinson and Company, Novo Nordisk A/S, and Owen Mumford are contributing to the growth of the market in North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Embecta Corp., Novo Nordisk A/S, Ypsomed AG, B. Braun Melsungen AG, Terumo Corporation, Nipro Corporation, Owen Mumford Limited, Arkray, Inc., UltiMed, Inc. and Allison Medical, Inc.
Recent Strategies Deployed in Pen Needles Market
Partnerships, Collaborations & Agreements:
Sep-2023: Novo Nordisk A/S came into partnership with Aspen Pharmacare Holdings Limited, a global pharmaceutical company. The partnership aimed at providing affordable human insulin to patients within the African continent.
May-2023: Embecta Corp. came into partnership with Tidepool, an AI-driven diabetes treatment solutions provider, to develop an automated insulin delivery system for the treatment of type 2 diabetes. The two companies would combine their respective offerings to facilitate glucose management within the patients to achieve the aim of their partnership.
Nov-2021: Terumo Corporation signed a partnership with Diabeloop, a therapeutic AI solutions provider, to provide Automated Insulin Delivery solutions to European customers. The partnership expands the two company's geographical footprint.
Product Launches and Product Expansions:
Oct-2022: Ypsomed AG released YpsoMate 5.5, an autoinjector platform for liquid medications with volumes within the 1.5 to 5.5 ml range. The product facilitates the self-administration of medicines to treat autoimmune diseases.
Sep-2022: Terumo Corporation announced the launch of FineGlide, a Sterile Pen Needle for facilitating regular insulin injections. The product has a 3-bevel sharp needle and a reliable silicone surface along with Thin Wall Technology for increasing flow rate that facilitates lesser injection force.
Dec-2021: Ypsomed AG introduced YpsoMate On, an autoinjector for prefilled syringes. The product is connectivity-enabled and can provide effective treatment for chronic diseases.
Dec-2021: Owen Mumford Limited announced the launch of Unifine Ultra, a home-use pen needle. The needle features an ergonomic design for facilitating easy use. Additionally, the needle includes Owen Mumford's SafeControl Technology which is used to secure both ends of the needle, thereby facilitating increased patient compliance.
Mergers & Acquisition:
Oct-2023: Novo Nordisk A/S acquired Biocorp Production, a French medical device manufacturer. The acquisition strengthens Novo Nordisk's devices and delivery solutions.
Geographical Expansions:
Mar-2023: Novo Nordisk A/S expanded its geographical footprint by opening a new R&D facility in Boston, United States. The new facility would serve as the premier US-based research and development activities hub for Novo Nordisk.
Market Segments covered in the Report:
By Type (Volume, Thousand Units, USD Billion/Million, 2019-2030)
By Setting (Volume, Thousand Units, USD Billion/Million, 2019-2030)
By Application (Volume, Thousand Units, USD Billion/Million, 2019-2030)
By Length
By Mode of Purchase (Volume, Thousand Units, USD Billion/Million, 2019-2030)
By Geography (Volume, Thousand Units, USD Billion/Million, 2019-2030)
Companies Profiled
Unique Offerings from KBV Research